Ongoing, recruitingTherapeutic confirmatory (Phase III)Interventional

A Continuation Study of Latozinemab in Participants with Neurodegenerative Disease

This is an ongoing study, picking up from previous research, that is looking into a medication called latozinemab. It's for people who have certain brain diseases that get worse over time, known as neurodegenerative diseases. The main goals are to understand more about how safe latozinemab is when taken over a longer period and to see if it makes a difference to people's health. Researchers will be carefully checking for any side effects and how participants are generally feeling. This study is in its final phase of testing before a medicine can potentially be made widely available.

At a glance

Status

Ongoing, recruiting

Phase

Therapeutic confirmatory (Phase III)

Sponsor

Alector LLC

Enrolment target

Start

20 Aug 2024

Neurodegenerative Diseases

What is this study about?

This research is a continuation of previous studies into a medication called latozinemab. It's designed for people living with neurodegenerative diseases, which are conditions that affect the brain and nerves and can gradually get worse over time. Often, these diseases can impact memory, thinking, and movement, and include conditions like Alzheimer's.

The main purpose of this study is to gather more information about latozinemab. Researchers want to understand how many people receive the medication and for how long they take it. They'll be keeping a close eye on safety, checking for any unexpected reactions or side effects, both mild and more serious ones.

Researchers will also be looking at how participants are generally doing during the study. They're particularly interested in changes to participants' condition every three months, using standard ways to measure how well someone is coping and how much their situation might be improving or staying stable. This helps them build a comprehensive picture of the medication's effects over time.

Key takeaways

This study is a follow-up for people already taking the medicine latozinemab.
It's for adults (18+) with brain conditions that worsen over time.
The main goals are to check the medicine's long-term safety and how well people are doing.
Participants will have regular check-ups every three months.
Both men and women can take part in this research.
It's a later stage study, gathering more evidence before potential wider use.

Who may be eligible?

To be considered for this study, you would generally need to be at least 18 years old. There isn't an upper age limit mentioned, meaning older adults could also be included.

Both men and women are welcome to participate in this research. The study aims to be as inclusive as possible regarding gender.

Crucially, participants would typically be people who have already taken part in an earlier study involving latozinemab for a neurodegenerative disease. This study is designed to continue observing the long-term effects in individuals who have already started the treatment.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have a neurodegenerative disease?
Have you previously taken part in a study for latozinemab?
Are you able to attend regular check-ups?
Are you comfortable with ongoing monitoring of your health?

Answer every question to see your result.

What does participation involve?

If you were to take part in this study, it would involve continuing to receive the latozinemab medication, as this is a follow-on study for people who have already been taking it. The duration of this treatment period will be carefully tracked by the researchers. You would have regular check-ups, probably every three months, where doctors would assess your general health and how your condition is progressing.

During these visits, healthcare professionals would ask you how you are feeling and look for any changes in your health or any new symptoms. They would also monitor for any side effects from the medication. This ongoing monitoring helps the research team understand the long-term safety and effects of latozinemab.

Potential risks and benefits

Participating in research always carries potential benefits and risks. A potential benefit of continuing in this study could be continued access to a new medication that might help manage your neurodegenerative condition. However, there's also a chance the medication may not work for you, or you might experience side effects. Researchers will carefully monitor you for any adverse events, which could range from mild to serious. It's very important to remember that joining a study is always your choice, and you have the right to withdraw at any time without explaining why, and this will not affect your usual medical care.

Locations (7)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Germany
—
Unverified
Portugal
—
Unverified
Italy
—
Unverified
Netherlands
—
Unverified
Belgium
—
Unverified
France
—
Unverified
Sweden

Common questions

What kind of conditions is this study looking at?

This study is for people with 'neurodegenerative diseases,' which are brain conditions that get worse over time, like Alzheimer's.

What is latozinemab?

Latozinemab is the name of the medicine being studied. It's being tested to see if it can help people with these brain conditions.

Am I too old to join?

No, there isn't an upper age limit mentioned for this study, and people over 18 can take part.

How often will I need to be seen?

It looks like you would have assessments and check-ups every three months during the study.

What if I change my mind about being in the study?

You are free to leave the study at any time, for any reason, and it won't affect your regular medical care.